Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Chemotherapy in Patients With Advanced Colorectal Carcinoma

NCT00005076 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT00005076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Chemotherapy in Patients With Advanced Colorectal Carcinoma
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Completed
Start date
October 31, 1999
Completion date
July 31, 2005
Enrollment
110 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer